Form 4: Inovio Pharmaceuticals Director Lota S. Zoth Reports Stock Transaction

Director Lota S. Zoth reports the vesting and acquisition of 2,166 shares of Inovio Pharmaceuticals common stock on May 15, 2024, related to restricted stock units.

Summary

• On May 15, 2024, Lota S. Zoth, a director of Inovio Pharmaceuticals, acquired 2,166 shares of common stock.
• The acquisition was due to the vesting of restricted stock units.
• These restricted stock units vested 100% on May 15, 2024, each representing a contingent right to receive one share of common stock.
• The reported transaction gives effect to a 1-for-12 reverse stock split that Inovio Pharmaceuticals implemented on January 24, 2024.
• Following the transaction, Zoth directly owns 6,559 shares of Inovio Pharmaceuticals.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock transactions by a company director. The vesting of restricted stock units is generally a positive sign, but it's a routine event.

Positives

• The vesting of restricted stock units indicates that performance milestones were likely met, which is a positive signal.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, such as directors, and their confidence in the company's prospects.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.

Key Dates